Week In Review: Suzhou Abogen Raises $700 Million For mRNA COVID-19 Vaccine
August 28, 2021 at 15:19 PM EDT
Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine. The company has completed a Phase II trial of the vaccine but hasn't released any data from the trial.